

Leanne M Ward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7926917/publications.pdf>

Version: 2024-02-01

118
papers

9,940
citations

50276

46
h-index

36028

97
g-index

123
all docs

123
docs citations

123
times ranked

7843
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. <i>JAMA Network Open</i> , 2022, 5, e2144178.	5.9	31
2	An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 113.	2.7	9
3	Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant. <i>Bone</i> , 2022, 160, 116400.	2.9	10
4	Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3241-e3253.	3.6	36
5	Preventing symptomatic vitamin D deficiency and rickets among Indigenous infants and children in Canada. <i>Paediatrics and Child Health</i> , 2022, 27, 127-127.	0.6	3
6	La prévention de la carence en vitamine D symptomatique et du rachitisme chez les nourrissons et les enfants autochtones du Canada. <i>Paediatrics and Child Health</i> , 2022, 27, 128-128.	0.6	0
7	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. <i>Calcified Tissue International</i> , 2021, 108, 622-633.	3.1	26
8	Beyond Bone Mineral Density: The Impact of Childhood Cancer and Its Treatment on Bone Structure and Strength. <i>Frontiers of Hormone Research</i> , 2021, 54, 1-22.	1.0	1
9	Part I: Which Child with a Chronic Disease Needs Bone Health Monitoring?. <i>Current Osteoporosis Reports</i> , 2021, 19, 278-288.	3.6	8
10	Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?. <i>Current Osteoporosis Reports</i> , 2021, 19, 289-297.	3.6	8
11	Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. <i>Cancer Medicine</i> , 2021, 10, 4177-4194.	2.8	13
12	Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-Treated Rheumatic Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5195-e5207.	3.6	4
13	Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-Induced Osteoporosis: A Randomized, Double-Blind, Phase 3 Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5222-e5235.	3.6	13
14	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 622-637.	11.4	29
15	The Effects of Physical Activity on Physical and Skeletal Development. <i>JBSJ Reviews</i> , 2021, 9, .	2.0	1
16	Disorders of Calcium, Phosphorus, and Bone Metabolism During Fetal and Neonatal Development. , 2020, , 755-782.		3
17	The Accuracy of Prevalent Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 460-468.	2.8	8
18	A Contemporary View of the Definition and Diagnosis of Osteoporosis in Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2088-e2097.	3.6	64

#	ARTICLE	IF	CITATIONS
19	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. <i>Clinical Pediatrics</i> , 2020, 59, 1080-1085.	0.8	6
20	Advances in the Bone Health Assessment of Children. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 613-636.	3.2	6
21	New developments in the management of achondroplasia. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 104-111.	1.1	18
22	The Accuracy of Incident Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1255-1268.	2.8	3
23	Glucocorticoid-Induced Osteoporosis: Why Kids Are Different. <i>Frontiers in Endocrinology</i> , 2020, 11, 576.	3.5	32
24	A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 2290-2299.	2.8	5
25	The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019, 22, 567-589.	1.2	83
26	Local Tumor Recurrence and Escape from Suppression of Bone Resorption With Denosumab Treatment in Two Adolescents With Giant Cell Tumors of Bone. <i>JBMR Plus</i> , 2019, 3, e10196.	2.7	11
27	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 2416-2427.	13.7	229
28	The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor-Treated Chronic Myelogenous Leukemia. <i>Journal of the Endocrine Society</i> , 2019, 3, 857-864.	0.2	6
29	Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 39-48.	2.3	23
30	Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 213-222.	3.6	11
31	Skeletal Morbidity in Children and Adolescents during and following Cancer Therapy. <i>Hormone Research in Paediatrics</i> , 2019, 91, 137-151.	1.8	35
32	Osteoporosis: Diagnosis and Management. , 2018, , 525-565.		3
33	Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. <i>Lancet Neurology</i> , The, 2018, 17, 251-267.	10.2	767
34	Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. <i>Lancet Neurology</i> , The, 2018, 17, 347-361.	10.2	668
35	Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. <i>Lancet Neurology</i> , The, 2018, 17, 445-455.	10.2	268
36	Anabolic Therapy for the Treatment of Osteoporosis in Childhood. <i>Current Osteoporosis Reports</i> , 2018, 16, 269-276.	3.6	21

#	ARTICLE	IF	CITATIONS
37	An Introduction to the Duchenne Muscular Dystrophy Care Considerations. <i>Pediatrics</i> , 2018, 142, S1-S4.	2.1	3
38	Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. <i>Pediatrics</i> , 2018, 142, S34-S42.	2.1	48
39	Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. <i>Pediatrics</i> , 2018, 142, S43-S52.	2.1	26
40	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. <i>Pharmacological Research</i> , 2018, 136, 140-150.	7.1	69
41	Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy. <i>Current Osteoporosis Reports</i> , 2018, 16, 541-553.	3.6	22
42	Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1435-1443.	2.8	79
43	Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017, 97, 287-292.	2.9	50
44	Yunis-Varã³n syndrome caused by biallelic VAC14 mutations. <i>European Journal of Human Genetics</i> , 2017, 25, 1049-1054.	2.8	21
45	Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta. <i>Osteoporosis International</i> , 2017, 28, 2095-2101.	3.1	29
46	Increased bone matrix mineralization in treatment-naÃ³ve children with inflammatory bowel disease. <i>Bone</i> , 2017, 105, 50-56.	2.9	11
47	Musculoskeletal health in newly diagnosed children with Crohnâ€™s disease. <i>Osteoporosis International</i> , 2017, 28, 3169-3177.	3.1	32
48	Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3111-3123.	3.6	170
49	The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. <i>Osteoporosis International</i> , 2017, 28, 597-608.	3.1	59
50	Rickets. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17101.	30.5	131
51	Severe vitamin D deficiency: A persistent yet preventable problem among Canadian youth. <i>Paediatrics and Child Health</i> , 2017, 22, 43-44.	0.6	2
52	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Pediatric Rheumatology</i> , 2017, 15, 68.	2.1	39
53	The impact of underlying disease on fracture risk and bone mineral density in children with rheumatic disorders: A review of current literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 49-63.	3.4	28
54	The management of osteoporosis in children. <i>Osteoporosis International</i> , 2016, 27, 2147-2179.	3.1	113

#	ARTICLE	IF	CITATIONS
55	Pigment epithelium-derived factor (PEDF) normalizes matrix defects in iPSCs derived from Osteogenesis imperfecta Type VI. <i>Rare Diseases (Austin, Tex)</i> , 2016, 4, e1212150.	1.8	3
56	The Spectrum of Recovery From Fracture-Induced Vertebral Deformity in Pediatric Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1107-1110.	1.5	17
57	Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1060-1069.	2.8	34
58	The Radiology of Vertebral Fractures in Childhood Osteoporosis Related to Glucocorticoid Administration. <i>Journal of Clinical Densitometry</i> , 2016, 19, 81-88.	1.2	16
59	Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. <i>Hormone Research in Paediatrics</i> , 2016, 85, 83-106.	1.8	158
60	Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions. <i>Calcified Tissue International</i> , 2016, 98, 76-84.	3.1	32
61	Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence. <i>PLoS ONE</i> , 2016, 11, e0146824.	2.5	45
62	Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1667-1675.	2.8	94
63	Incidence and characteristics of vitamin D deficiency rickets in New Zealand children: a New Zealand Paediatric Surveillance Unit study. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 380-383.	1.8	40
64	Common normal variants of pediatric vertebral development that mimic fractures: a pictorial review from a national longitudinal bone health study. <i>Pediatric Radiology</i> , 2015, 45, 593-605.	2.0	49
65	The Choice of Normative Pediatric Reference Database Changes Spine Bone Mineral Density Z-Scores But Not the Relationship Between Bone Mineral Density and Prevalent Vertebral Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1018-1027.	3.6	51
66	Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3408-3417.	3.6	93
67	A154: Glucocorticoid Therapy and the Risk of Incident Vertebral Fracture in Children with Rheumatic Disorders. <i>Arthritis and Rheumatology</i> , 2014, 66, S199-S200.	5.6	5
68	Nucleus-targeted Dmp1 transgene fails to rescue dental defects in Dmp1 null mice. <i>International Journal of Oral Science</i> , 2014, 6, 133-141.	8.6	7
69	Observer agreement in pediatric semiquantitative vertebral fracture diagnosis. <i>Pediatric Radiology</i> , 2014, 44, 457-466.	2.0	24
70	Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. <i>Osteoporosis International</i> , 2014, 25, 627-637.	3.1	45
71	A21: Physical Activity in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise,) Tj ETQq1 1 0.784314 rgBT /Overlook S33-S34.	5.6	7
72	Bone Health in Children and Adolescents With Chronic Diseases That May Affect the Skeleton: The 2013 ISCD Pediatric Official Positions. <i>Journal of Clinical Densitometry</i> , 2014, 17, 281-294.	1.2	119

#	ARTICLE	IF	CITATIONS
73	The development of bone mineral lateralization in the arms. <i>Osteoporosis International</i> , 2013, 24, 999-1006.	3.1	2
74	Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. <i>Arthritis Care and Research</i> , 2013, 65, 113-121.	3.4	18
75	Infantile Malignant Osteopetrosis. <i>Journal of Pediatrics</i> , 2013, 163, 1230-1230.e1.	1.8	11
76	Oral bisphosphonates for paediatric osteogenesis imperfecta?. <i>Lancet, The</i> , 2013, 382, 1388-1389.	13.7	11
77	Report of the CCFA Pediatric Bone, Growth and Muscle Health Workshop, New York City, November 11-12, 2011, With Updates. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2919-2926.	1.9	18
78	High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2760-2767.	1.6	120
79	The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. <i>Osteoporosis International</i> , 2012, 23, 2703-2711.	3.1	115
80	Incidence of vitamin D deficiency rickets among Australian children: an Australian Paediatric Surveillance Unit study. <i>Medical Journal of Australia</i> , 2012, 196, 466-468.	1.7	104
81	Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines. <i>Osteoporosis International</i> , 2012, 23, 1999-2008.	3.1	48
82	Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study. <i>Arthritis Care and Research</i> , 2012, 64, 122-131.	3.4	121
83	Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. <i>Osteoporosis International</i> , 2012, 23, 751-760.	3.1	54
84	Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children. <i>Clinical Therapeutics</i> , 2011, 33, 1516-1523.	2.5	11
85	Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome. <i>Pediatric Nephrology</i> , 2011, 26, 139-142.	1.7	29
86	Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis. <i>European Journal of Endocrinology</i> , 2011, 164, 295-301.	3.7	28
87	Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 355-364.	3.6	184
88	Bisphosphonate therapy for children and adolescents with secondary osteoporosis. <i>The Cochrane Library</i> , 2010, 2010, CD005324.	2.8	87
89	Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. <i>Osteoporosis International</i> , 2010, 21, 331-337.	3.1	66
90	<i>DMP1</i> C-terminal mutant mice recapture the human ARHR tooth phenotype. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2155-2164.	2.8	29

#	ARTICLE	IF	CITATIONS
91	Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. <i>Arthritis Care and Research</i> , 2010, 62, 516-526.	3.4	124
92	Use of bisphosphonates in the treatment of pediatric osteoporosis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 657-672.	0.3	15
93	A case of moyamoya syndrome and hemoglobin E/beta α -thalassemia. <i>Pediatric Blood and Cancer</i> , 2009, 52, 422-424.	1.5	15
94	Advanced Vertebral Fracture Among Newly Diagnosed Children With Acute Lymphoblastic Leukemia: Results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Research Program. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1326-1334.	2.8	188
95	Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. <i>Bone</i> , 2009, 44, 287-294.	2.9	66
96	FGF23 and hypophosphatemia: Clinical aspects. <i>Bone</i> , 2009, 45, S49-S50.	2.9	0
97	Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 400-409.	3.6	206
98	Impaired muscle function and tibial bone deficits in children with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S19.	1.9	0
99	Dual Energy X-ray Absorptiometry Interpretation and Reporting in Children and Adolescents: The 2007 ISCD Pediatric Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 43-58.	1.2	480
100	Efficacy of food fortification on serum 25-hydroxyvitamin D concentrations: systematic review. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1528-1534.	4.7	96
101	Vitamin D-deficiency rickets among children in Canada. <i>Cmaj</i> , 2007, 177, 161-166.	2.0	278
102	Effect of Calcium and Vitamin D Supplementation on Bone Mineral Density in Children With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 45, 538-545.	1.8	48
103	Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. <i>Nature Genetics</i> , 2006, 38, 1310-1315.	21.4	1,063
104	Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2055-2061.	3.6	214
105	Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. <i>Nature Genetics</i> , 2005, 37, 25-27.	21.4	321
106	Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4051-4056.	3.6	54
107	Vitamin D deficiency in the 21st century: a persistent problem among Canadian infants and mothers. <i>Cmaj</i> , 2005, 172, 769-770.	2.0	44
108	Osteoporosis due to Glucocorticoid Use in Children with Chronic Illness. <i>Hormone Research in Paediatrics</i> , 2005, 64, 209-221.	1.8	39

#	ARTICLE	IF	CITATIONS
109	Renal phosphate-wasting disorders in childhood. <i>Pediatric Endocrinology Reviews</i> , 2005, 2 Suppl 3, 342-50.	1.2	3
110	Maternal and Fetal Outcome After Long-Term Pamidronate Treatment Before Conception: A Report of Two Cases. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1742-1745.	2.8	97
111	Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. <i>Bone</i> , 2004, 34, 905-911.	2.9	66
112	Genetic changes in the RNA components of RNase MRP and RNase P in Schmid metaphyseal chondrodysplasia. <i>Journal of Medical Genetics</i> , 2003, 40, 741-746.	3.2	20
113	The Spectrum of Pediatric Osteoporosis. , 2003, , 401-442.		26
114	Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. <i>Bone</i> , 2002, 31, 12-18.	2.9	241
115	Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. <i>Bone</i> , 2002, 31, 19-25.	2.9	66
116	Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 30-38.	2.8	403
117	Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1650-1658.	2.8	440
118	A Novel A10E Homozygous Mutation in the HSD3B2 Gene Causing Severe Salt-Wasting 3 β -Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after Puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1968-1974.	3.6	27